spacer
The Healthcare Sales & Marketing Network celebrates 22 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Macugen 

 HSMN NewsFeed - 29 May 2013
Ophthotech Raises $175 Million to Finance the Pivotal Phase 3 Program for Fovista(TM) Anti-PDGF Combination Therapy in Wet AMD
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 13 Feb 2012
Valeant Pharmaceuticals to Acquire Eyetech
Biopharmaceuticals Ophthalmology Mergers & Acquisitions
 HSMN NewsFeed - 29 Jan 2010
Study Published in the American Journal of Ophthalmology Examines Investigational Use of Macugen in Patients With Branch Retinal Vein Occlusion (BRVO)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 15 Dec 2009
Ophthotech Raises $30 Million in Series B Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 18 Jun 2008
Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Aug 2007
Ophthotech Raises $36 Million; In-Licenses Two Compounds for Macular Degeneration
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 27 Jul 2007
OSI Pharmaceuticals Announces Agreement to Divest Anti-Platelet Derived Growth Factor (PDGF) Program
Biopharmaceuticals Ophthalmology Acquisitions
 HSMN NewsFeed - 23 Jul 2007
Merrimack Pharmaceuticals Names William Slichenmyer, M.D. Senior Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Feb 2007
Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 2 Nov 2006
Enzon Pharmaceuticals Announces Second Investigational New Drug Application Approved for Novel rhMBL
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Oct 2006
EyeGate Pharma Starts U.S. Operations in Waltham, MA
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 24 Oct 2006
Acuity Pharmaceuticals Appoints Denis O'Shaughnessy Senior Vice President of Clinical Development
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 21 Sep 2006
OSI Pharmaceuticals Launches Study of Tarceva(R) as Adjuvant Treatment for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Aug 2006
Enzon Pharmaceuticals Announces Advancements in Its Oncology Pipeline
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jul 2006
OSI Pharmaceuticals Announces That Roche Has Received Negative CHMP Opinion in European Union on Tarceva(R) in Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Jul 2006
Enzon Pharmaceuticals and Santaris Pharma Enter into Global Collaboration to Develop Novel Cancer Therapeutics
Biopharmaceuticals Licensing
 HSMN NewsFeed - 25 Jul 2006
FDA Approves Enzon's Oncaspar(R) for First-Line Use in Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Jul 2006
Alexion Pharmaceuticals Appoints David L. Hallal Vice President U.S. Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jun 2006
OSI Pharmaceuticals and Pfizer Announce Phase IV Macugen(R)(pegaptanib sodium injection) Maintenance Trial in Neovascular Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 5 Jun 2006
Results From a Randomized Phase II Trial Suggested the Combinations of Avastin(R) Plus Tarceva(R) and Avastin Plus Chemotherapy Improved Progression- Free Survival in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2006
Preliminary Topline Efficacy Results from Phase II Data Show Macugen(R) (pegaptanib sodium injection) Maintained or Improved Vision in over 90 Percent of Patients with Macular Edema Associated with Central Retinal Vein Occlusion (CRVO)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 4 May 2006
OSI Pharmaceuticals Summarizes Macugen(R) (pegaptanib sodium injection) Data Presented at Association for Research in Vision and Ophthalmology (ARVO) Meeting
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 May 2006
OSI Pharmaceuticals Announces Management Changes to Its Eye Disease Business Team
Biopharmaceuticals Personnel Ophthalmology
 HSMN NewsFeed - 18 Apr 2006
Lpath Introduces Ocular Division
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 17 Apr 2006
OSI Pharmaceuticals Announces Submission of New Drug Application for Tarceva(R) in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Apr 2006
Enzon Initiates Clinical Program for ONCASPAR(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Feb 2006
Clarus Ventures Expands Investment Team
Venture Capital Personnel
 HSMN NewsFeed - 2 Feb 2006
OSI Pharmaceuticals Announces European Regulatory Approval for Macugen(R) (pegaptanib sodium injection)
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 2 Feb 2006
European Commission Approves Macugen for Treatment of All Types of Wet Age-Related Macular Degeneration; First Treatment to Target Underlying Disease Process of Wet AMD
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 1 Feb 2006
OSI Pharmaceuticals Announces Fourth Quarter Net Sales for Tarceva(R)'s International Launch
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jan 2006
PR Pharmaceuticals (PRP) Announces Collaboration With OSI Pharmaceuticals to Develop Sustained Release Formulation of Macugen(R) (pegaptanib sodium injection)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 6 Jan 2006
Enzon Returns Rights to Transplantation Product to Fresenius Biotech
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 40

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 40 additional stories matching:
Macugen
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.